Search
Menu
Home
HTB
2000
May
HTB
May 2000
Contents
Treatment alerts
EMEA public statement on Viramune (nevirapine): severe and life-threatening cutaneous and hepatic reactions
Conference reports
Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA
Clinical studies of indinavir/ritonavir as salvage therapy
Indinavir plus ritonavir: might exposure to higher levels of indinavir overcome protease resistant HIV and prove useful to ‘rescue’ previously failed protease inhibitor based combinations?
First International Workshop in Clinical Pharmacology in HIV Therapy, 30-31 March 2000, Noordwijk, Netherlands
TDM: standardisation and quality control
TDM in clinical practice
ATHENA – Early results from first randomised study of clinical benefits of TDM
TDM for individualising dosing – practicality and efficacy for PIs and RTIs
TDM and adherence
Drug interactions: amprenavir, saquinavir, ABT-378/r (lopinavir/r), indinavir, efavirenz, ritonavir
L-Acetyl Carnitine (LAC) improves symptoms of peripheral neuropathy (PN): evidence for increases in cutaneous innervation
Antiretrovirals
ABT-378/r (lopinavir) now available on named patient basis in UK
Enteric coated ddI available on named patient basis in UK
Nelfinavir potency concerns
Treatment strategies
GM-CSF beneficial for patients with advanced HIV disease
Paediatric care
Liquid formulation of efavirenz available for children in the uk on named patient basis
Most reconstituted CD4 cells naive after HAART in children with HIV
Side effects
Decreased bone mineral density and HIV protease inhibitors
Other news
A view from the lab: interview with Professor Clive Loveday
PDFs
Volume 1 Number 2 May 2000 PDF
HTB RSS
Early access
Latest statistics on HIV in the UK: data for 2021
1 December 2022
All early access reports
Current issues
January 2023
December 2022
October 2022
Back issues
Special report
Latest statistics on HIV in the UK: data for 2021
1 December 2022
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage